Severe osteogenesis imperfecta: New therapeutic options?

British Medical Journal

Volumn 322, Issue 7278, 2001, Pages 63-64

  Smith, R ^a  

^a NUFFIELD ORTHOPAEDIC CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

BONE MARROW TRANSPLANTATION; COLLAGEN METABOLISM; EDITORIAL; GENE MUTATION; HUMAN; OSTEOGENESIS IMPERFECTA; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0035852455     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.322.7278.63     Document Type: Editorial

References (11)

1. Osteogenesis imperfecta: Managing brittle bones
2. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta
3. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta
4. Bisphosphonates: From the laboratory to the clinic and back again
5. Long term effects of bisphosphonates on the growing skeleton. Studies of young patients with severe osteoporosis
6. Intravenous pamidronate treatment in osteogenesis imperfecta
7. Marrow stromal cells as a source of progenitor cells for non haematopoietic tissues in transgenic mice with a phenotype of osteogenesis imperfecta
8. Osteogenesis imperfecta calls for caution
9. Osteogenesis imperfecta calls for caution
10. Mesenchymal stem cells: No longer second class marrow citizens
11. Marked clinical and radiographic improvement in infantile hypophosphatasia transiently after haploidentical bone marrow transplantation